ZC3H12D and hepatocellular carcinoma: The negative association between expression of these CTAs in TFL and HCC-recurrence and patient survival, independent of clinical and histological tumor characteristics, combined with immunohistochemisry data showing scattered CTA-expressing cells in TFL, suggests that CTA-expressing (pre-)malignant cells remain present in the liver after tumor resection, and are indicative for the potential relevance of therapeutic targeting of these antigens.